biostudies-literatureEspinet BNIAID NIH HHS1007-19https://www.ebi.ac.uk/biostudies/studies/S-EPMC4488901biostudies-literatureUnknown20(4)<h4>Purpose</h4>According to current diagnostic criteria, mantle cell lymphoma (MCL) encompasses the usual, aggressive variants and rare, nonnodal cases with monoclonal asymptomatic lymphocytosis, cyclin D1-positive (MALD1). We aimed to understand the biology behind this clinical heterogeneity and to identify markers for adequate identification of MALD1 cases.<h4>Experimental design</h4>We compared 17 typical MCL cases with a homogeneous group of 13 untreated MALD1 cases (median follow-up, 71 months). We conducted gene expression profiling with functional analysis in five MCL and five MALD1. Results were validated in 12 MCL and 8 MALD1 additional cases by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and in 24 MCL and 13 MALD1 cases by flow cytometry. ClassificatioClinical cancer research : an official journal of the American Association for Cancer ResearchDistinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry.PMC4488901R01 AI057653Serrano SFerrer ASanz FBellosillo BOrfao ANavarro JTGarcia-Garcia MFlorensa LSalar ALuno EGimeno JNonell LAbrisqueta PCerutti AEspinet BLloreta JDominguez-Sola DSole FMinana Bde la Banda EArenillas LCollado RSerrano CFernandez-Rodriguez CPuigdecanet EVela MCfalseDistinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry.<h4>Purpose</h4>According to current diagnostic criteria, mantle cell lymphoma (MCL) encompasses the usual, aggressive variants and rare, nonnodal cases with monoclonal asymptomatic lymphocytosis, cyclin D1-positive (MALD1). We aimed to understand the biology behind this clinical heterogeneity and to identify markers for adequate identification of MALD1 cases.<h4>Experimental design</h4>We compared 17 typical MCL cases with a homogeneous group of 13 untreated MALD1 cases (median follow-up, 71 months). We conducted gene expression profiling with functional analysis in five MCL and five MALD1. Results were validated in 12 MCL and 8 MALD1 additional cases by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and in 24 MCL and 13 MALD1 cases by flow cytometry. Classificatio2014-01-01T00:00:00Z2014 Feb2026-05-30T13:42:18.62Z2026-04-08T07:20:07.692ZS-EPMC44889012435264610.1158/1078-0432.CCR-13-107710.1158/1078-0432.ccr-13-1077